hidden pixel

Imipramine Information

Imipramine (sold as Antideprin, Deprimin, Deprinol, Depsol, Depsonil, Dynaprin, Eupramin, Imipramil, Irmin, Janimine, Melipramin, Surplix, Tofranil), also known as melipramine, is an antidepressant medication, a tricyclic antidepressant of the dibenzazepine group. Imipramine is mainly used in the treatment of major depression and enuresis (inability to control urination).

It has also been evaluated for use in panic disorder.[1]

Contents

Therapeutic uses

Imipramine is used in the treatment of depression, such as depression associated with agitation or anxiety and has similar efficacy to the antidepressant drug moclobemide.[2]

History

Imipramine was, in the late 1950s, the first tricyclic antidepressant to be developed (by Ciba). It was first tried against psychotic disorders, such as schizophrenia, but proved insufficient. As an antidepressant, it did well in clinical studies and it is known to work well in even the most severe cases of depression.[3] It is not surprising, therefore, that Imipramine is also known to cause a high rate of manic and hypomanic reactions, especially in patients with preexisting bipolar disorder. It is estimated that up to 25% of such patients maintained on Imipramine will switch into mania or hypomania.[4] Such powerful antidepressant properties have made it favorable in the treatment of treatment-resistant depression.

At the advent of SSRIs, its sometimes intolerable side-effect profile became more tolerable. Therefore, it became extensively used as a standard antidepressant and later served as a prototypical drug for the development of the later-released tricyclics. It is not as commonly used today, but is sometimes used to treat major depression as a second-line treatment. It has also seen limited use in the treatment of migraines, ADHD, and post concussive syndrome. Imipramine has additional indications for the treatment of panic attacks, chronic pain, and Kleine-Levin syndrome. In pediatric patients, it is relatively frequently used to treat pavor nocturnus and nocturnal enuresis.

Mechanism of action

Imipramine, a tertiary amine, affects numerous neurotransmitter systems known to be involved in the etiology of depression, anxiety , ADHD, enuresis and numerous other mental and physical conditions. Imipramine is similar in structure to some muscle relaxants, and has a significant analgesic effect and, thus, is very useful in some pain conditions.

The mechanisms of Imipramine's medicinal action include, but are not limited to, effects on:

Comparison with other antidepressants

The potency (affinity) of imipramine and other antidepressant on various transporters and receptors are summarized below. Data are from "Pharmacology of antidepressant", Mayo Clin Proc, May 2001, Vol 76.[8]

Potency (affinity) data are expressed as the inverse of equilibrium dissociation constant multiplied by a factor of 10−7. So, the higher the number, the higher the blocking power.

Drug SERT NET DAT α1 blockade D2 blockade H1 blockade muscarinic blockade 5HT2 blockade
imipramine 70 2.7 0.012 1.5 0.05 9.1 1.1 1.2
desipramine (also an imipramine metabolite) 5.7 128 0.024 0.77 0.03 0.91 0.5 0.38
amitriptyline 23 2.9 0.023 3.7 0.1 91 5.6 3.4
clomipramine 360 2.7 0.045 2.6 0.53 3.2 2.7 3.7
paroxetine 800 2.5 0.2 0.025 0.003 0.03 0.93 0.005
citalopram 98 0.035 0.0038 0.053 0 0.21 0.045 0.34

Metabolism

Imipramine is converted to desipramine, another TCA, in the body.

Side effects

Those listed in Italic text below denote common side effects. Those listed in bold text denote life-threatening side effects.[9]

Dosage

Overdose

Main article: Tricyclic antidepressant overdose

The symptoms and the treatment of an imipramine overdose are largely the same as for the other tricyclic antidepressants. Cardinal symptoms are cardiac (tachycardia, widened QRS complex) and neurological disturbances. Any ingestion by children should be considered as serious and potentially fatal.

See also

References

  1. ^ Lepola U, Arató M, Zhu Y, Austin C (June 2003). "Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder". J Clin Psychiatry 64 (6): 654–62. doi:10.4088/JCP.v64n0606. PMID 12823079. http://www.psychiatrist.com/privatepdf/2003/v64n06/v64n0606.pdf.
  2. ^ Delini-Stula A, Mikkelsen H, Angst J (October 1995). "Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies". J Affect Disord 35 (1–2): 21–30. doi:10.1016/0165-0327(95)00034-K. PMID 8557884.
  3. ^ Healy, David: The Antidepressant Era, page 211. Harvard University Press, 1997.
  4. ^ Bottlender R, Rudolf D, Strauss A, Möller HJ (1998). "Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression". European Archives of Psychiatry and Clinical Neuroscience 248 (6): 296–300. doi:10.1007/s004060050053. PMID 9928908.
  5. ^ Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (April 2006). "Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action". Nature Neuroscience 9 (4): 519–25. doi:10.1038/nn1659. PMID 16501568.
  6. ^ Krishnan V, Nestler EJ (October 2008). "The molecular neurobiology of depression". Nature 455 (7215): 894–902. Bibcode 2008Natur.455..894K. doi:10.1038/nature07455. PMC 2721780. PMID 18923511. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2721780.
  7. ^ Effects of imipramine administration on mu-opioid receptor immunostaining in the rat forebrain. de Gandarias JM, Echevarria E, Acebes I, Silio M, Casis L. 1: Arzneimittelforschung. 1998 Jul;48(7):717-9 http://www.ncbi.nlm.nih.gov/pubmed/9706370
  8. ^ Richelson E (May 2001). "Pharmacology of antidepressants". Mayo Clinic Proceedings. Mayo Clinic 76 (5): 511–27. doi:10.4065/76.5.511. PMID 11357798.
  9. ^ Skidmore-Roth, L.(ed.). (2010). Mosby's Nursing Drug Reference (23rd ed.). St. Louis, MO: Mosby Elsevier.

External links

Antidepressants (N06A)
Specific reuptake inhibitors (RIs), enhancers (REs), and releasing agents (RAs)
Selective serotonin reuptake inhibitors (SSRIs)
Serotonin–norepinephrine reuptake inhibitors (SNRIs)
Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs)
Norepinephrine reuptake inhibitors (NRIs)
Dopamine reuptake inhibitors (DRIs)
Norepinephrine-dopamine reuptake inhibitors (NDRIs)
Norepinephrine-dopamine releasing agents (NDRAs)
Serotonin-norepinephrine-dopamine releasing agents (SNDRAs)
Selective serotonin reuptake enhancers (SSREs)
Others
Receptor antagonists and/or reuptake inhibitors
Serotonin antagonists and reuptake inhibitors (SARIs)
Noradrenergic and specific serotonergic antidepressants (NaSSAs)
Norepinephrine-dopamine disinhibitors (NDDIs)
Serotonin modulators and stimulators (SMSs)
Others
Heterocyclic antidepressants (bi-, tri-, and tetracyclics)
Bicyclics
Tricyclics
Tetracyclics
Monoamine oxidase inhibitors (MAOIs)
Nonselective
MAOA-Selective
MAOB-Selective
Azapirones and other 5-HT1A receptor agonists

: PSO/PSI

(, , , , , , ), /,

proc(/), drug(/////)

Anxiolytics (N05B)
GABAA PAMs
Benzodiazepine AdinazolamAlprazolamBretazenilBromazepamCamazepamChlordiazepoxideClobazamClonazepamClorazepateClotiazepamCloxazolamDiazepamEthyl LoflazepateEtizolamFludiazepamHalazepamImidazenilKetazolamLorazepamMedazepamNordazepamOxazepamPinazepamPrazepam
Carbamates EmylcamateMebutamateMeprobamate (Carisoprodol, Tybamate) • PhenprobamateProcymate
Nonbenzodiazepines AbecarnilAdipiplonAlpidem • CGS-8216 • CGS-9896 • CGS-13767 • CGS-20625DivaplonELB-139FasiplonGBLD-345GedocarnilL-838,417NS-2664NS-2710OcinaplonPagoclonePanadiplonPipequalineRWJ-51204SB-205,384SL-651,498TaniplonTP-003TP-13TPA-023Y-23684ZK-93423
Pyrazolopyridines CartazolateEtazolateICI-190,622Tracazolate
Others ChlormezanoneEthanol (Alcohol) • EtifoxineKavalactones (Kava Kava) • SkullcapValerenic Acid (Valerian)
α2δ VDCC Blockers GabapentinPregabalin
5-HT1A Agonists Azapirones: BuspironeGepironeTandospirone; Others: FlesinoxanOxaflozane
H1 Antagonists Diphenylmethanes: CaptodiameHydroxyzine; Others: BrompheniramineChlorpheniraminePheniramine
CRH1 Antagonists AntalarminCP-154,526PexacerfontPivagabine
NK2 Antagonists GR-159,897Saredutant
MCH1 antagonists ATC-0175SNAP-94847
mGluR2/3 Agonists Eglumegad
mGluR5 NAMs Fenobam
TSPO agonists DAA-1097DAA-1106EmapunilFGIN-127FGIN-143
σ1 agonists AfobazoleOpipramol
Others BenzoctamineCarbetocinDemoxytocinMephenoxaloneMepiprazoleOxanamideOxytocinPromoxolaneTofisopamTrimetozineWAY-267,464

: PSO/PSI

(, , , , , , ), /,

proc(/), drug(/////)

Adrenergics
Receptor ligands
α1
α2
β
Reuptake inhibitors
NET
VMAT
Releasing agents
Enzyme inhibitors
Anabolism
PAH
TH
AAAD
DBH
PNMT
  • CGS-19281A
  • SKF-64139
  • SKF-7698
Catabolism
MAO
COMT
Others
Precursors
Cofactors
Others
List of adrenergic drugs
Cholinergics
Receptor ligands
mAChR
nAChR
Reuptake inhibitors
Plasmalemmal
CHT Inhibitors
Vesicular
VAChT Inhibitors
Enzyme inhibitors
Anabolism
ChAT inhibitors
  • 1-(-Benzoylethyl)pyridinium
  • 2-(α-Naphthoyl)ethyltrimethylammonium
  • 3-Chloro-4-stillbazole
  • 4-(1-Naphthylvinyl)pyridine
  • Acetylseco hemicholinium-3
  • Acryloylcholine
  • AF64A
  • B115
  • BETA
  • CM-54,903
  • N,N-Dimethylaminoethylacrylate
  • N,N-Dimethylaminoethylchloroacetate
Catabolism
AChE inhibitors
BChE inhibitors
  • Cymserine * Many of the acetylcholinesterase inhibitors listed above act as butyrylcholinesterase inhibitors.
Others
Precursors
Cofactors
Others
Histaminergics
Receptor ligands
H1
H2
H3
H4
Reuptake inhibitors
Vesicular
VMAT inhibitors
Enzyme inhibitors
Anabolism
HDC inhibitors
Catabolism
HNMT inhibitors
DAO inhibitors
Others
Precursors
Cofactors
Serotonergics
5-HT1 receptor ligands
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2 receptor ligands
5-HT2A
5-HT2B
5-HT2C
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Reuptake inhibitors
SERT
VMAT
Releasing agents
Enzyme inhibitors
Anabolism
TPH
AAAD
Catabolism
MAO
Others
Precursors
Cofactors
Others
Tricyclics
Classes
Antidepressants
Antihistamines
Antipsychotics
Others

Categories:

 

The above information uses material from Wikipedia and is licensed under the GNU Free Documentation License.
Some facts may not have been fully verified for accuracy. [Disclaimers]
This page was last archived by our server on Tue Apr 17 13:10:32 2012.
Displaying this page or its contents does not use any Wikimedia Foundation's resources.
The owners of this site proudly support the Wikimedia Foundation.